ChromaDex (Nasdaq:CDXC) - Hisse Senedi Fiyatı, Haberler ve Analizler

CDXC Stoklara Genel Bakış

ChromaDex Corporation, sağlıklı yaşlanma ürünleri geliştirmeye odaklanan bir biyobilim şirketi olarak faaliyet göstermektedir. Daha fazla detay

CDXC temel anali̇z
Kar Tanesi Skoru
Değerleme	1/6
Gelecekteki Büyüme	4/6
Geçmiş Performans	3/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 10.3% daha düşük bir oranda işlem görüyor

Kazançların yılda 81.83% oranında artması öngörülüyor

Bu yıl karlı hale geldi

Risk Analizi

Son 3 ayda hisse senedi fiyatı oldukça dalgalıydı

ChromaDex Corporation Rakipler

Mesa Laboratories

NasdaqGS:MLAB

US$541.8m

Pacific Biosciences of California

NasdaqGS:PACB

US$471.0m

Quanterix

NasdaqGM:QTRX

US$424.5m

Standard BioTools

NasdaqGS:LAB

US$562.1m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti ChromaDex
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$7.50
52 Haftanın En Yüksek Seviyesi	US$7.67
52 Haftanın En Düşük Seviyesi	US$1.32
Beta	1.88
11 Aylık Değişim	116.76%
3 Aylık Değişim	127.96%
1 Yıllık Değişim	417.24%
33 Yıllık Değişim	50.00%
5 Yıllık Değişim	96.34%
Halka arzdan bu yana değişim	-33.33%

Son Haberler & Güncellemeler

ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors

Nov 07

Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

Nov 05

Recent updates

ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors

Nov 07

Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

Nov 05

ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

Jul 25

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Jun 15

Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

Jun 05

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

Apr 05

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

Feb 28

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Jan 29

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

Jun 08

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Mar 31

ChromaDex inks new commercial supply agreement for its Niagen ingredient with Nestlé

Oct 11

ChromaDex wins patent challenge as US regulator rejects Thorne Research's demand to invalidate patent

Aug 15

Hissedar Getirileri

	CDXC	US Life Sciences	US Pazar
7D	7.0%	-5.8%	-1.0%
1Y	417.2%	1.7%	30.3%

Getiri vs. Endüstri: CDXC geçen yıl % 1.7 oranında getiri sağlayan US Life Sciences sektörünü aştı.

Getiri vs Piyasa: CDXC geçen yıl % 30.3 oranında getiri sağlayan US Piyasasını aştı.

Fiyat Oynaklığı

Is CDXC's price volatile compared to industry and market?
CDXC volatility
CDXC Average Weekly Movement	20.4%
Life Sciences Industry Average Movement	8.8%
Market Average Movement	6.2%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: CDXC hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: CDXC 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 15% dan 20% a yükseldi.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1999	106	Rob Fried	www.chromadex.com

ChromaDex Corporation, sağlıklı yaşlanma ürünleri geliştirmeye odaklanan bir biyobilim şirketi olarak faaliyet göstermektedir. Şirket üç segmentte faaliyet göstermektedir: Tüketici ürünleri; Bileşenler; ve Analitik Referans Standartları ve Hizmetleri. Nikotinamid adenin dinükleotid (NAD+) araştırmaları yapar; tescilli bileşenlerini içeren bitmiş besin takviyesi ürünlerini doğrudan tüketicilere ve distribütörlere sunar; ve tescilli bazlı bileşen teknolojileri geliştirir ve ticarileştirir ve bu bileşenleri tüketici ürünleri üreticilerine hammadde olarak tedarik eder.

ChromaDex Corporation Temel Bilgiler Özeti

ChromaDex'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CDXC temel i̇stati̇sti̇kler
Piyasa değeri	US$575.66m
Kazançlar(TTM)	US$1.49m
Gelir(TTM)	US$91.67m

386.6x

F/K Oranı

6.3x

P/S Oranı

CDXC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CDXC gelir tablosu (TTM)
Gelir	US$91.67m
Gelir Maliyeti	US$35.34m
Brüt Kâr	US$56.33m
Diğer Giderler	US$54.84m
Kazançlar	US$1.49m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.019
Brüt Marj	61.45%
Net Kâr Marjı	1.62%
Borç/Özkaynak Oranı	0%

CDXC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

CDXC Stoklara Genel Bakış

Ödüller

Risk Analizi

ChromaDex Corporation Rakipler

NasdaqGS:MLAB

US$541.8m

NasdaqGS:PACB

US$471.0m

NasdaqGM:QTRX

US$424.5m

NasdaqGS:LAB

US$562.1m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Now 21% undervalued

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors

Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

ChromaDex Corporation Provides Earnings Guidance for the Full Year of 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Recent updates

Now 21% undervalued

ChromaDex's Pharmaceutical-Grade Niagen® IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide

ChromaDex's (NASDAQ:CDXC) Solid Earnings Are Supported By Other Strong Factors

Revenues Tell The Story For ChromaDex Corporation (NASDAQ:CDXC) As Its Stock Soars 70%

ChromaDex Corporation Provides Earnings Guidance for the Full Year of 2024

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation to Report Q3, 2024 Results on Oct 31, 2024

Chromadex Corporation Announces Chief Financial Officer Changes

Independent Director notifies of intention to sell stock

ChromaDex Corporation announced that it expects to receive $32.058489 million in funding

Price target increased by 7.6% to US$6.54

Forecast breakeven date moved forward to 2024

Second quarter 2024 earnings released: EPS: US$0 (vs US$0.029 loss in 2Q 2023)

ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024

ChromaDex Corporation (NASDAQ:CDXC) Stock Rockets 25% But Many Are Still Ignoring The Company

ChromaDex Corporation to Report Q2, 2024 Results on Aug 07, 2024

ChromaDex Corporation Appoints Carlos Lopez as Senior Vice President, General Counsel

ChromaDex Corp Shares Results from a Milestone Phase II Clinical Study Showing the Promising Effects of Nicotinamide Riboside (NR) Supplements for People with Peripheral Artery Disease

Shareholders Will Likely Find ChromaDex Corporation's (NASDAQ:CDXC) CEO Compensation Acceptable

Chromadex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen®

Positive Sentiment Still Eludes ChromaDex Corporation (NASDAQ:CDXC) Following 26% Share Price Slump

New major risk - Share price stability

Consensus EPS estimates fall from profit to US$0.008 loss

ChromaDex Corporation Reiterates Earnings Guidance for the Full Year of 2024

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased by 9.6% to US$6.28

ChromaDex Corporation, Annual General Meeting, Jun 20, 2024

ChromaDex Corporation to Report Q1, 2024 Results on May 08, 2024

Should You Think About Buying ChromaDex Corporation (NASDAQ:CDXC) Now?

New minor risk - Share price stability

Consensus EPS estimates have been upgraded.

Price target increased by 13% to US$5.53

Price target decreased by 9.3% to US$4.94

Full year 2023 earnings: EPS exceeds analyst expectations

Not Many Are Piling Into ChromaDex Corporation (NASDAQ:CDXC) Just Yet

ChromaDex Corporation to Report Q4, 2023 Results on Mar 06, 2024

ChromaDex Corporation's (NASDAQ:CDXC) Intrinsic Value Is Potentially 85% Above Its Share Price

Neurohacker Collective and Chromadex Partner to Optimize Cellular Health with the Debut of Qualia Nad+

Ch ChromaDex Corp. shares results from a new breakthrough study analyzing the safety of high-dose nicotinamide riboside (NR) supplementation on individuals with Parkinson's disease (PD)

Chromadex Corp. Shares Results from Phase II Clinical Study

Consensus EPS estimates upgraded to US$0.088 loss

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

ChromaDex Corporation Provides Revenue Guidance for the Year 2023

Price target decreased by 11% to US$4.88

ChromaDex Corp. Debuts Clinical Strength Tru Niagen®? Pro 1,000Mg Featuring Niagen®? (Patented Nicotinamide Riboside)

ChromaDex Corporation to Report Q3, 2023 Results on Nov 08, 2023

ChromaDex Corp. and Zesty Paws Crack the Code on Cellular Health for Dogs With ‘Healthy Aging’ Line

New minor risk - Market cap size

Chromadex Announces Results from Newly Published Clinical Study, as Reported in the Peer-Reviewed Journal Cell Reports, Demonstrating That Supplementation with Nicotinamide Riboside

Consensus EPS estimates upgraded to US$0.12 loss

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation to Report Q2, 2023 Results on Aug 09, 2023

ChromaDex Corp. Announces Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD) in Glaucoma Patients and That Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects

Market Cool On ChromaDex Corporation's (NASDAQ:CDXC) Revenues

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

ChromaDex Corporation Provides Revenue Guidance for the Full Year 2023

We're Hopeful That ChromaDex (NASDAQ:CDXC) Will Use Its Cash Wisely

Consensus EPS estimates fall by 24%

Full year 2022 earnings: EPS misses analyst expectations